Q2 2021 Earnings Estimate for Allena Pharmaceuticals, Inc. Issued By Wedbush (NASDAQ:ALNA)

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) – Stock analysts at Wedbush increased their Q2 2021 earnings per share (EPS) estimates for shares of Allena Pharmaceuticals in a report issued on Wednesday, May 12th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.26). Wedbush also issued estimates for Allena Pharmaceuticals’ Q3 2021 earnings at ($0.19) EPS, Q4 2021 earnings at ($0.18) EPS, FY2021 earnings at ($0.78) EPS, Q1 2022 earnings at ($0.20) EPS, Q2 2022 earnings at ($0.21) EPS, Q3 2022 earnings at ($0.22) EPS, Q4 2022 earnings at ($0.24) EPS, FY2022 earnings at ($0.86) EPS, FY2023 earnings at ($1.44) EPS, FY2024 earnings at ($1.63) EPS and FY2025 earnings at ($1.14) EPS.

Allena Pharmaceuticals (NASDAQ:ALNA) last announced its quarterly earnings data on Monday, May 10th. The company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01.

Separately, Zacks Investment Research cut Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Shares of ALNA stock opened at $1.10 on Friday. The stock has a 50 day moving average of $1.24 and a two-hundred day moving average of $1.46. The company has a current ratio of 7.99, a quick ratio of 7.99 and a debt-to-equity ratio of 0.54. Allena Pharmaceuticals has a 12 month low of $1.02 and a 12 month high of $3.39. The company has a market capitalization of $63.37 million, a P/E ratio of -0.87 and a beta of 2.39.

A number of institutional investors have recently bought and sold shares of the business. Worth Venture Partners LLC boosted its stake in Allena Pharmaceuticals by 24.8% in the fourth quarter. Worth Venture Partners LLC now owns 510,200 shares of the company’s stock worth $653,000 after purchasing an additional 101,360 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Allena Pharmaceuticals by 96.7% in the first quarter. Renaissance Technologies LLC now owns 485,930 shares of the company’s stock worth $675,000 after purchasing an additional 238,919 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Allena Pharmaceuticals by 178.9% during the first quarter. Geode Capital Management LLC now owns 256,244 shares of the company’s stock valued at $356,000 after acquiring an additional 164,371 shares during the period. BlackRock Inc. lifted its stake in shares of Allena Pharmaceuticals by 15.7% during the first quarter. BlackRock Inc. now owns 189,802 shares of the company’s stock valued at $264,000 after acquiring an additional 25,746 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Allena Pharmaceuticals during the first quarter valued at $54,000. 28.03% of the stock is currently owned by institutional investors.

In other Allena Pharmaceuticals news, COO Louis Md Brenner sold 25,215 shares of the business’s stock in a transaction on Monday, May 10th. The stock was sold at an average price of $1.11, for a total value of $27,988.65. Following the transaction, the chief operating officer now owns 203,322 shares of the company’s stock, valued at $225,687.42. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 22.80% of the company’s stock.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Further Reading: What is a capital gain?

Earnings History and Estimates for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.